Transforming growth factor-β and tumor

Abstract

Tang Nailing, Guo Zhi, Yang Xueling. Transforming growth factor-β and tumor[J]. Journal of International Oncology, 2015, 42(1): 43-45.

［1］ Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition［J］. J Clin Invest, 2009, 119(6): 1420-1428. ［2］ Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion［J］. Cancer Metastasis Rev, 2009, 28(1-2): 15-33. ［3］ Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease［J］. Annu Rev Cell Dev Biol, 2011, 27: 347-376. ［4］ Lamouille S, Derynck R. Cell size and invasion in TGFbetainduced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway［J］. J Cell Biol, 2007, 178(3): 437-451. ［5］ Shin JA, Hong OK, Lee HJ, et al. Transforming growth factorβ induces epithelial to mesenchymal transition and suppresses the proliferation and transdifferentiation of cultured human pancreatic duct cells［J］. J Cell Biochem, 2011, 112(1): 179-188. ［6］ Mu Y, Gudey SK, Landstrm M. NonSmad signaling pathways［J］. Cell Tissue Res, 2012, 347(1): 11-20. ［7］ Nam JS, Terabe M, Kang MJ, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin17［J］. Cancer Res, 2008, 68(10): 3915-3923. ［8］ Nam JS, Terabe M, Mamura M, et al. An antitransforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments［J］. Cancer Res, 2008, 68(10): 38353843. ［9］ Drabsch Y, ten Dijke P. TGFβ signaling in breast cancer cell invasion and bone metastasis［J］. J Mammary Gland Biol Neoplasia, 2011, 16(2): 97-108. ［10］ Hu Z, Zhang Z, Guise T, et al. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptorⅡFc fusion protein can inhibit breast cancer bone metastasis in a mouse model［J］. Hum Gene Ther, 2010, 21(11): 1623-1629. ［11］ Lonning S, Mannick J, McPherson JM. Antibody targeting of TGFβ in cancer patients［J］. Curr Pharm Biotechnol, 2011, 12(12): 2176-2189. ［12］ Schlingensiepen KH, Jaschinski F, Lang SA, et al. Transforming growth factorbeta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer［J］. Cancer Sci, 2011, 102(6): 1193-1200. ［13］ Hau P, Jachimczak P, Schlingensiepen R, et al. Inhibition of TGFbeta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase Ⅰ/Ⅱ studies［J］. Oligonucleotides, 2007, 17(2): 201-212. ［14］ Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for highgrade glioma with the TGFβ2 inhibitor trabedersen: results of a randomized and controlled phase Ⅱb study［J］. Neuro Oncol, 2011, 13(1): 132-142. ［15］ Strimpakos AS, Syrigos KN, Saif MW. Novel agents and new combination treatments on phase Ⅰ studies on solid tumors and pancreatic cancer［J］. JOP, 2012, 13(4): 345-348. ［16］ Tanaka H, Shinto O, Yashiro M, et al. Transforming growth factor β signaling inhibitor, SB431542, induces maturation of dendritic cells and enhances antitumor activity［J］. Oncol Rep, 2010, 24(6): 1637-1643. ［17］ Takeuchi K, Abe M, Hiasa M, et al. TgfBeta inhibition restores terminal osteoblast differentiation to suppress myeloma growth［J］. PLoS One, 2010, 5(3): e9870. ［18］ Connolly EC, Saunier EF, Quigley D, et al. Outgrowth of drugresistant carcinomas expressing markers of tumor aggression after longterm TβRⅠ/Ⅱ kinase inhibition with LY2109761［J］. Cancer Res, 2011, 71(6): 2339-2349. ［19］ Serizawa M, Takahashi T, Yamamoto N, et al. Combined treatment with erlotinib and a transforming growth factorβ type Ⅰ receptor inhibitor effectively suppresses the enhanced motility of erlotinibresistant nonsmallcell lung cancer cells［J］. J Thorac Oncol, 2013, 8(3): 259-269. ［20］ Rodon J, Carducci MA, SepulvedaSanchez JM, et al. Firstinhuman dose study of the Novel transforming growth factorβ receptor Ⅰ kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma［J］. Clin Cancer Res, 2014, In press. ［21］ Saito RA, Watabe T, Horiguchi K, et al. Thyroid transcription factor1 inhibits transforming growth factorbetamediated epithelialtomesenchymal transition in lung adenocarcinoma cells［J］. Cancer Res, 2009, 69(7): 2783-2791. ［22］ Bi X, Pohl NM, Qian Z, et al. Decorinmediated inhibition of colorectal cancer growth and migration is associated with Ecadherin in vitro and in mice［J］. Carcinogenesis, 2012, 33(2): 326-330.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments